Biohaven Pharmaceutical Holding Co. Ltd. (BHVN)
| Market Cap | 5.11B |
| Revenue (ttm) | 28.51M |
| Net Income (ttm) | -410.44M |
| Shares Out | 59.68M |
| EPS (ttm) | -12.30 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $84.91 |
| Previous Close | $91.75 |
| Change ($) | -6.84 |
| Change (%) | -7.46% |
| Day's Open | 91.24 |
| Day's Range | 84.47 - 92.39 |
| Day's Volume | 580,642 |
| 52-Week Range | 27.51 - 98.24 |
NEW HAVEN, Conn., Jan. 7, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the "Company" or "Biohaven") today announced the acquisition of the remaining 58% inter...
Biohaven (BHVN) initiates enrollment in a phase III study to evaluate troriluzole as adjunctive treatment for patients with obsessive-compulsive disorder.
NEW HAVEN, Conn., Jan. 4, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven") today announced that it has commenced enrollment in a Phase 3 clinical tri...
Investors need to pay close attention to Biohaven (BHVN) stock based on the movements in the options market lately.
NEW HAVEN, Conn., Dec. 16, 2020 /PRNewswire/ --- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) announced today that The Lancet published the company's positive results from a Phase...
Biohaven is establishing a comprehensive suite of migraine medicines. The company has an exciting pipeline of interesting late stage products.
MOORESVILLE, N.C., Dec. 2, 2020 /PRNewswire/ -- Biohaven Pharmaceuticals (NYSE:BHVN) announces today that Nurtec™ ODT (rimegepant) will be the primary partner for the No. 51 Rick Ware Racing e...
TOKYO and CAMBRIDGE, England, Dec. 1, 2020 /PRNewswire/ -- Sosei Group Corporation ("the Company") (TSE: 4565) announces it has entered into a global collaboration and license agreement with B...
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider b...
"I hope that in six months or so from now that we will be the first oral CGRP with the indication for the prevention of migraine," Biohaven CEO Vlad Coric said.
Biohaven Pharmaceutical CEO on efforts to prevent migraine with oral CGRP
CEO Vlad Coric said Biohaven, a biotech firm with a new product to treat migraines, plans to have a drug that can prevent migraines in the next sixth months.
NEW HAVEN, Conn., Nov. 16, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-sta...
NEW HAVEN, Conn., Nov. 11, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, best-in-...
Biohaven's (BHVN) recently approved migraine drug, Nurtec ODT, continues to demonstrate strong launch uptake.
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) CEO Vlad Coric on Q3 2020 Results - Earnings Call Transcript
Shares of Biohaven Pharmaceutical (NYSE:BHVN) traded flat in pre-market trading after the company reported Q3 results.
Biohaven (BHVN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Let us take a look at some drug/biotech stocks that are poised to beat on third-quarter earnings.
NEW HAVEN, Conn., Oct. 30, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-sta...
While the market driven by short-term sentiment influenced by the accomodative interest rate environment in the US, virus news and stimulus talks, many smart money investors are starting to ge...
Biohaven (BHVN) is seeking the label expansion of its migraine drug Nurtec ODT as a preventive treatment of migraine.
NEW HAVEN, Conn., Oct. 14, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the U.S. Food and Drug Administration (FDA) has filed and accepte...
NEW HAVEN, Conn., Sept. 10, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.
A Relative Strength Rating upgrade for BiohavenPharmaHldg shows improving technical performance.
Biohaven Is Still A Bargain On Increasing Nurtec ODT Sales
Biohaven Pharmaceutical Holding Company Ltd (BHVN) CEO Vladimir Coric on Q2 2020 Results - Earnings Call Transcript
Biohaven's (BHVN) recently approved migraine drug, Nurtec ODT, demonstrates strong launch uptake.
NEW HAVEN, Conn., Aug. 10, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.
NEW HAVEN, Conn., Aug. 7, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.
Biohaven will receive up to $250 million to fund zavegepant's development in migraine and non-migraine indications
NEW HAVEN, Conn., Aug. 3, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.
NEW HAVEN, Conn., July 21, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.
Biohaven Pharmaceutical Holding Co. Ltd.'s (NYSE: BHVN) "Nurtec ODT" drug will be promoted by media personality Khloe Kardashian, the company announced Wednesday.
Khloe Kardashian is working with Biohaven Pharmaceuticals to promote its newly launched migraine drug, Nurtec ODT.
Biohaven CEO on teaming with Khloé Kardashian on new migraine campaign
Biohaven Pharmaceuticals CEO Vlad Coric discussed launching Nurtec ODT, a drug to combat migraines, and what inspired celebrity Khloé Kardashian to get on board.
Biohaven Pharmaceutical delivered mixed results for its OCD treatment test on Wednesday — leading BHVN stock to tumble. Biohaven studied a drug called troriluzole in OCD patients.
NEW HAVEN, Conn., June 16, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), today announced that it presented data from 25 accepted abstracts demonstrating the e...
NEW HAVEN, Conn., June 10, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), today announced the appointment of pharmaceutical industry leader Robert J. Hugin to ...
A hot new migraine drug, positive financials, and several promising drug candidates in late-stage trials are luring investors to this stock.
NEW HAVEN, Conn., May 18, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), announced today that it will present data from 25 accepted abstracts demonstrating the...
Biohaven Pharmaceutical Offers Good Value With Nurtec ODT Now On The Market
Biohaven (BHVN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
RBC Capital has peered into its crystal ball to reveal some of the market's most exciting biotech stocks. Here are seven that stand out.
Biohaven CEO says new migraine treatment is a 'game changer for patients'
Biohaven CEO Vlad Coric discusses Nurtec ODT, the pharmaceutical company's newly launched oral tablet for migraines, and the importance of listening to patients.
The drug enters a crowded market -- but it has a convenient format.
Meta-Analysis Suggested That Biohaven Pharmaceutical's Migraine Prevention Trial Is Highly Likely To Succeed
Biohaven’s shares dropped after a failed clinical trial, and risk-tolerant investors are snapping them up.
The company's candidate troriluzole failed to meet its primary endpoint in a trial as a treatment for generalized anxiety disorder.
Shares of Biohaven Pharmaceutical tumbled Monday after its drug, troriluzole, failed to pass muster as an anxiety medicine. The biotech is still testing troriluzole in three other diseases.
Shares of Biohaven Pharmaceutical Holding Company Ltd. BHVN, -5.18% tumbled 16% in premarket trading on Monday after the company said its experimental treatment for generalized anxiety disorde...
About BHVN
Biohaven Pharmaceutical Holding Company, a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases and rare disorders in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials for acute treatment and prevention of migraine; Vazegepant that has completed Phase 2/3 trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias. The compan... [Read more...]
| Industry Biotechnology | IPO Date May 4, 2017 |
| CEO Vlad Coric | Employees 647 |
| Stock Exchange NYSE | Ticker Symbol BHVN |
Analyst Forecasts
The average 12-month stock price forecast for BHVN is 97.73, which is an increase of 15.10% from the latest price.